<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0EB2ECE2-59F9-4A04-B774-3F3EFD049686"><gtr:id>0EB2ECE2-59F9-4A04-B774-3F3EFD049686</gtr:id><gtr:name>Icahn School of Medicine at Mount Sinai</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/47A19BC3-1395-402D-8C69-FB62D261798E"><gtr:id>47A19BC3-1395-402D-8C69-FB62D261798E</gtr:id><gtr:name>Federal University of Minas Gerais</gtr:name><gtr:address><gtr:line1>Av. Antonio Carlos, 6627, Pampulha</gtr:line1><gtr:line2>6627 - Pampulha</gtr:line2><gtr:postCode>31270-901</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Brazil</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D6C3234E-5048-4AA0-A116-0CAC51569B2D"><gtr:id>D6C3234E-5048-4AA0-A116-0CAC51569B2D</gtr:id><gtr:name>University of Queensland</gtr:name><gtr:address><gtr:line1>University of Queensland</gtr:line1><gtr:line4>Brisbane</gtr:line4><gtr:line5>Queensland 4972</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0EB2ECE2-59F9-4A04-B774-3F3EFD049686"><gtr:id>0EB2ECE2-59F9-4A04-B774-3F3EFD049686</gtr:id><gtr:name>Icahn School of Medicine at Mount Sinai</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/47A19BC3-1395-402D-8C69-FB62D261798E"><gtr:id>47A19BC3-1395-402D-8C69-FB62D261798E</gtr:id><gtr:name>Federal University of Minas Gerais</gtr:name><gtr:address><gtr:line1>Av. Antonio Carlos, 6627, Pampulha</gtr:line1><gtr:line2>6627 - Pampulha</gtr:line2><gtr:postCode>31270-901</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Brazil</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D6C3234E-5048-4AA0-A116-0CAC51569B2D"><gtr:id>D6C3234E-5048-4AA0-A116-0CAC51569B2D</gtr:id><gtr:name>University of Queensland</gtr:name><gtr:address><gtr:line1>University of Queensland</gtr:line1><gtr:line4>Brisbane</gtr:line4><gtr:line5>Queensland 4972</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3C8A544E-00F6-4FA9-B14D-1F04B5B50A56"><gtr:id>3C8A544E-00F6-4FA9-B14D-1F04B5B50A56</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Howard</gtr:otherNames><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BD6339DF-6706-4458-ACAD-49C246900497"><gtr:id>BD6339DF-6706-4458-ACAD-49C246900497</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:otherNames>F</gtr:otherNames><gtr:surname>Dominiczak</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/27AAF6C2-069D-4BD2-AADC-D947F93F4322"><gtr:id>27AAF6C2-069D-4BD2-AADC-D947F93F4322</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Nicklin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/48C13E55-28C1-4AE4-BA67-521BE128FE74"><gtr:id>48C13E55-28C1-4AE4-BA67-521BE128FE74</gtr:id><gtr:firstName>Graeme</gtr:firstName><gtr:surname>Milligan</gtr:surname><gtr:orcidId>0000-0002-6946-3519</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901161"><gtr:id>0A43DC3F-4EEA-4F99-A56C-70CF7414C49D</gtr:id><gtr:title>Dissecting the mechanism of action of the renin angiotensin hormone angiotensin1-9</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901161</gtr:grantReference><gtr:abstractText>The body produces specific hormones which travel via the bloodstream and engage with receptors which contribute to the normal function of blood vessels, the heart and kidney. The main hormone from this system, angiotensin II, can become overactive and contribute to the development of cardiovascular disease, resulting in high blood pressure (hypertension) and finally enlargement of the heart and damage to kidneys. Although this has been known for a long time (in fact inhibitors of various facets of angiotensin II function are the target for a common group of drugs used to lower blood pressure in patients and treat conditions such as heart failure) the central mechanisms for the functioning of this hormone system are not completely understood. The hormone system has many different roles in the body depending upon the organ on which it acts. Also, new members of this hormone family are being discovered. Here we describe a role for a new hormone in this system, angiotensin 1-9. Angiotensin 1-9 was previously thought to be inactive but we have evidence to support it being an active hormone which inhibits angiotensin II actions. Thus angiotensin 1-9 may be an important therapeutic target in cardiovascular disease. We wish to full understand how this hormone functions and will achieve this using a range of techniques.</gtr:abstractText><gtr:technicalSummary>The renin angiotensin system (RAS) plays a key role in the development of cardiovascular diseases, including hypertension, cardiac hypertrophy and atherosclerosis. Although cell signalling via the peptide hormone angiotensin (Ang) II is well documented, other peptide hormones, particularly Ang1-7, for example, are also important in the pleiotrophic effects of the RAS in vivo and may antagonise AngII signalling. We have made a novel observation, outlined in supporting data, that the angiotensin metabolite Ang1-9, previously thought to be inactive, is actually an active RAS hormone in its own right. Ang1-9 engages the angiotensin type 2 receptor and is able to inhibit pro-hypertrophic signalling of AngII and other agonists on cardiomyocytes. In this proposal we will fully investigate and dissect the cell signalling mechanisms and in vivo functioning of Ang1-9 with regard to its effects on the heart and cardiomyocytes.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>383504</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Queensland</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>School of Biomedical Sciences Queensland</gtr:department><gtr:description>Gene transfer of angiotensin receptors</gtr:description><gtr:id>1006F112-90F4-4309-9220-C486D0E8382D</gtr:id><gtr:impact>The research publication listed in publications was supported by this collaboration. Conference proceedings published in Hypertension
The collaboration is not multi-disciplinary</gtr:impact><gtr:outcomeId>eZuzsxG4Ab6-1</gtr:outcomeId><gtr:partnerContribution>Provided reagents that directly enabled laboratory research to enhance the project and critical appraisal of the data.</gtr:partnerContribution><gtr:piContribution>Performed experiments with supplied reagents and shared the data for discussion</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Federal University of Minas Gerais</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>INCT- Nanobiofar- Robson Santos</gtr:description><gtr:id>55761E38-C7DC-4CB2-83FD-1F096171386F</gtr:id><gtr:impact>Grant application submitted and awaiting outcome</gtr:impact><gtr:outcomeId>54479f97af8939.07575583-1</gtr:outcomeId><gtr:partnerContribution>The lead PI Professor Robson Santos is at the university</gtr:partnerContribution><gtr:piContribution>Formal international collaborator on this large international grant application which is focused on developing new drugs of cardiometabolic diseases based on nanotechnology and the pharmacological and molecular characterization of components of RAS and related systems</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Icahn School of Medicine at Mount Sinai</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>The Zena and Michael A. Wiener Cardiovascular Institute</gtr:department><gtr:description>Training in in vivo techniques- aortic banding</gtr:description><gtr:id>6F378240-61EB-46F7-A3B7-575775C2AA4C</gtr:id><gtr:impact>not aplicable</gtr:impact><gtr:outcomeId>kQVVX7fdLT5-1</gtr:outcomeId><gtr:partnerContribution>Provided detailed training over a period of two weeks in surgical techniques. Met and discussed research with PDRA.</gtr:partnerContribution><gtr:piContribution>The PDRA from our group visited the USA lab to give a talk, meet with researchers and learn a new in vivo technique.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Scottish Science Advisory Board Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EB03B045-23DA-47AE-A21A-67AD4194A723</gtr:id><gtr:impact>engagment and interest of broader audience to my research

not applicable.</gtr:impact><gtr:outcomeId>JcLyBRkRK5m</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MP and MSP Visit to Research Institute</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DD1E00F1-862C-4A65-AA0A-0F17BE8E81A4</gtr:id><gtr:impact>Invited to take part in an informal discussion/ presentation hosted by the British Heart Foundation in Scotland with local MPs and MSPs regarding current funding and types of research being done in Glasgow.</gtr:impact><gtr:outcomeId>56b07322db19d6.96154427</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>447000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L019108/1</gtr:fundingRef><gtr:id>A9C98F55-1264-4DE6-9BD7-7F9181BEED05</gtr:id><gtr:outcomeId>5447a378581578.49128682</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF 4 Year PhD Studentship Scheme</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>82F0B246-AA90-46BF-95CA-7C60AB3D8171</gtr:id><gtr:outcomeId>r1QVh2KaXKu</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTG</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8EA61315-A260-41CD-BC5E-558219EB575C</gtr:id><gtr:outcomeId>sMkXPPRc8o2</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF 4 Year PhD Studentship Scheme</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>BA5956BF-8F2F-4828-A334-A74FC4C9EE71</gtr:id><gtr:outcomeId>MJiXA2Dhvw8</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>210000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/11/43/28901</gtr:fundingRef><gtr:id>2904462B-6F39-4E82-9326-4A7C86C6C051</gtr:id><gtr:outcomeId>h721F1DwgSD</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF 4 Year PhD Studentship Scheme</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>4FFAA98F-21E5-4EAC-8D9E-218C277C87D5</gtr:id><gtr:outcomeId>CheQDuwXHou</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>036DB294-63E6-47D3-8709-E996CBE62AAB</gtr:id><gtr:title>Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system.</gtr:title><gtr:parentPublicationTitle>Future cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99fe7911882cfa0e38fdf01f8fc60a77"><gtr:id>99fe7911882cfa0e38fdf01f8fc60a77</gtr:id><gtr:otherNames>Clarke C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1479-6678</gtr:issn><gtr:outcomeId>nhRVAp6zsk3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0566CD00-5C42-4C0E-B9EB-1B09B00B0E1B</gtr:id><gtr:title>Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling.</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76f8938c46511f1bd42e1044961d201a"><gtr:id>76f8938c46511f1bd42e1044961d201a</gtr:id><gtr:otherNames>McKinney CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0143-5221</gtr:issn><gtr:outcomeId>pm_540e16be16be7a9f5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F664AE0-B725-45A6-BB08-AD87503C4E40</gtr:id><gtr:title>Investigating the role of Angiotensin (1-9) in a mouse model of Angiotensin II-induced hypertension.</gtr:title><gtr:parentPublicationTitle>Journal of Hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3470379f7d5f1718966e50259fd2848"><gtr:id>a3470379f7d5f1718966e50259fd2848</gtr:id><gtr:otherNames>Flores-Munoz Monica</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>tAyvp9zxwqZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CE4FCAE-CDEC-4612-A1A2-283004674E8D</gtr:id><gtr:title>Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2890053faf10c83a6a6a7c0b6cb26634"><gtr:id>2890053faf10c83a6a6a7c0b6cb26634</gtr:id><gtr:otherNames>Fattah C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>588b62b3650b73.14982458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C47E2EDD-4A95-441E-B490-E2050EEEF7D5</gtr:id><gtr:title>Angiotensin-(1-9) antagonises Angiotensin II-induced cardiac remodeling via the angiotensin type 2 receptor.</gtr:title><gtr:parentPublicationTitle>Proceedings of the Physiological Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3470379f7d5f1718966e50259fd2848"><gtr:id>a3470379f7d5f1718966e50259fd2848</gtr:id><gtr:otherNames>Flores-Munoz Monica</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>UDcziaC2x61</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61071A1C-ED45-4589-A885-109ACCB7D325</gtr:id><gtr:title>Angiotensin1-9 Antagonises Cardiomyocyte Hypertrophy via the Angiotensin Type 2 Receptor</gtr:title><gtr:parentPublicationTitle>HYPERTENSION</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3470379f7d5f1718966e50259fd2848"><gtr:id>a3470379f7d5f1718966e50259fd2848</gtr:id><gtr:otherNames>Flores-Munoz Monica</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0194-911X</gtr:issn><gtr:outcomeId>feDXpBs4KiW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55F0BE5C-881D-4A10-AE35-963BD5E8F35E</gtr:id><gtr:title>Assessing the effects of Angiotensin-(1-9) in cardiac remodeling in a mouse model of Angiotensin II-induced hypertension.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3470379f7d5f1718966e50259fd2848"><gtr:id>a3470379f7d5f1718966e50259fd2848</gtr:id><gtr:otherNames>Flores-Munoz Monica</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>WVRSRXUzjkF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5B43506-EB85-4353-ACFE-148344398D52</gtr:id><gtr:title>'ANGIOTENSIN-(1-7) AND ANGIOTENSIN-(1-9) INHIBIT HUMAN VASCULAR SMOOTH MUSCLE CELL MIGRATION: EFFECTS ON MIR-132 AND PHOSPHATASE AND TENSIN HOMOLOGUE EXPRESSION</gtr:title><gtr:parentPublicationTitle>Clinical science (London, England : 1979)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eef55d8225f031c1f388de941c28da03"><gtr:id>eef55d8225f031c1f388de941c28da03</gtr:id><gtr:otherNames>McKinney Clare A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>kAv3mAbUgbx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>055404A6-69F6-443C-BC01-DA2D52215387</gtr:id><gtr:title>Angiotensin-(1-9) antagonises cardiac remodelling via the angiotensin type 2 receptor</gtr:title><gtr:parentPublicationTitle>EUROPEAN HEART JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b52e3de738fc0eb4af1bffe83979293"><gtr:id>3b52e3de738fc0eb4af1bffe83979293</gtr:id><gtr:otherNames>Flores-Munoz M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>LF4Myrj3FEP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F07EE2F3-D319-4E89-AFF6-01480CE2E0C5</gtr:id><gtr:title>195 Angiotensin-(1-9) Reduces Cardiac Dysfunction in a Model of Angiotensin II-Induced Hypertensive Heart Disease</gtr:title><gtr:parentPublicationTitle>Heart</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3df79e304e8c907dc62a0ddb0ceb2f15"><gtr:id>3df79e304e8c907dc62a0ddb0ceb2f15</gtr:id><gtr:otherNames>Nather K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56b06e97221c19.40003481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E870B2A-EDCE-4D86-BBFF-7E8B4845157E</gtr:id><gtr:title>Angiotensin-(1-9) antagonises cardiac remodelling in a mouse model of Angiotensin II-induced hypertension.</gtr:title><gtr:parentPublicationTitle>Hypertension</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3470379f7d5f1718966e50259fd2848"><gtr:id>a3470379f7d5f1718966e50259fd2848</gtr:id><gtr:otherNames>Flores-Munoz Monica</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>F9w5WcjL6D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F66E3B2-48FC-4A3C-80D8-21EB72DFC01A</gtr:id><gtr:title>Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51a0b0af6b0ce2fd92459657a217e0b5"><gtr:id>51a0b0af6b0ce2fd92459657a217e0b5</gtr:id><gtr:otherNames>Flores-Mu?oz M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>CtatDJAmaDC</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901161</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>